NanoVibronix, Inc. (NAOV)

Market Cap	12.21M
Revenue (ttm)	2.03M
Net Income (ttm)	-11.58M
Shares Out	28.00M
EPS (ttm)	-0.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	253,727
Open	0.446
Previous Close	0.460
Day's Range	0.430 - 0.446
52-Week Range	0.420 - 2.210
Beta	0.69
Analysts	Buy
Price Target	n/a
Earnings Date	Nov 14, 2022

About NAOV

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and j...

• Industry: Health Care Equipment & Supplies
• Founded: 2003
• CEO: Brian Murphy
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: NAOV

Full Company Profile

Financial Performance

In 2021, NanoVibronix's revenue was $1.70 million, an increase of 172.07% compared to the previous year's $623,000. Losses were -$14.28 million, 230.1% more than in 2020.

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target

n/a

Analyst Consensus: Buy

Stock Forecasts